QIBA Profile:

  1. Clinical context(Michael)
  2. Gain insight into microstructural and compositional changes in tumors due to treatmentvia DWI and ADC mapping
  3. Claims(Michael)
  4. Using monoexponential fitting of DW-MRI data acquired at 1.5T or 3.0T, tissue water mobility in tumors can be characterized using ADCb1-b2 with a 15% test / retest coefficient of variation. This clam holds for solid tumors greater than 1 cm in diameter, or twice the slice thickness, whichever is greater.
  5. Profile detail/protocol
  6. Executive Summary(Michael)
  7. Word about what is the state of the art in research and clinical trials
  8. Why would standardization help
  9. Few sentences what this profile is for.
  10. Context of the imaging protocol within the clinical trial(Thorsten)
  11. High level summary of what the imaging is for and what it will allow to do
  12. Role of imaging in a response to therapy assessment
  13. Therapy related effects as a consequence to therapy
  14. Site selection, Qualification and training(Tom)
  15. Phantom studies, other pre-requisites for being able to do the studies mentioned in this profile
  16. Equipment
  17. Phantom
  18. Process of site qualification
  19. Mechanism in place to train and educate the site on
  20. Challenges to profile use(Alex)
  21. Necrotic components
  22. Hemorrhages
  23. Lipid-rich tumors
  24. Mucin-rich tumors
  25. Susceptibility effects
  26. Subject scheduling(Thorsten)
  27. Subject preparation(Thorsten)
  28. General preparation
  29. Motion-specific preparation
  30. Imaging Procedure
  31. b-values(Michael)
  32. Number and choice of b-values
  33. Preferred: 3 b-value minimum (constant TE)
  34. Acceptable: 2 b-value (0, and high)
  35. Number of averages per b-value
  36. Detailed description of imaging protocols, based on area of body
  37. Motion(Marko)
  38. Breath hold
  39. Gating- cardiac or respiratory
  40. Sequence type(Dave [Siemens], Greg [Philips], Sandeep [GE] for 2-8)
  41. FOV, matrix size, slice thickness
  42. 3 orthogonal gradients for each b-value>0
  43. Single vs double echo
  44. Single vs multishot
  45. Parallel imaging
  46. Fat-suppression techniques, per region, 1.5 vs 3T
  47. Imaging post-processing(Brendan Whicker, Hendrik)
  48. Image distortion correction
  49. Motion
  50. Image Analysis(Brendan, Hendrik)
  51. ROI protocol
  52. Contrast bolus administration, if necessary
  53. T2W ROI
  54. Use of DWI image for ROI
  55. Challenges
  56. Obtaining anADC value
  57. Fit
  58. Pixelwise,whole Tumor Mean/Median, histogram
  59. Image interpretation(Alex, Mark)
  60. Statistics to calculate from resulting maps
  61. Tumor segmentation
  62. Single operator
  63. ADC changes with treatment
  64. Archival and distribution of data(Michael)
  65. Archiving segmentations
  66. Saving segmentation masks (numeric)
  67. Quality control(Martin Buechert)
  68. List all sources of artifact and variation and procedures to mitigate them
  69. Prospective
  70. Perfusion at low b-value
  71. Subject motion
  72. Acq. Plane
  73. Image artifacts (wrap, metal, etc…)
  74. Retrospective
  75. Registration methods
  76. Adherence to imaging protocols
  77. Imaging-associated risks and risk management(MIchael)
  78. Compliance
  79. Site
  80. Scanner
  81. Software
  82. Appendices
  83. perfusion effects in various tissues